Ricardo Baptista-Leite

Dr. Ricardo Baptista-Leite

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2017 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
MPMaria da Conceição Constantino Portela
Maria da Conceição Constantino Portela
CSCarlos Sinogas
Carlos Sinogas
FAFernando Albuquerque de Almeida
Fernando Albuquerque de Almeida
RBRicardo Baptista-Leite
Ricardo Baptista-Leite
ACAlexandre Castro-Caldas
Alexandre Castro-Caldas
Introduction: Medicinal products of a biological origin are approved by the EMA at a centralized level. However, there is no harmonization about their use in Europe. The current regulation referring to the safety of biological medicinal products and biosimilars in Europe has been identified. The safety associated with medicinal products of a biological origin is assured by the pharmacovigilance system, which has evolved, but doesn’t yet incorporate all of the specific information from this market segment, namely that related to the identification of drugs, and its use – including the prescription and dispensing, given the possibility of interchangeability and substitution. The terminology, information systems and traceability systems aren’t entirely appropriate to ensure the safety requirements for therapy with medicinal products of a biological origin. Areas covered: This article aims to identify the prescription and dispensing profiles of reference biological medicines and biosimilars in the EU, and the determinants that support their safe use. Expert opinion: The European pharmacovigilance system must evolve to ensure the safety along all of the biologicals’ therapeutic cycle. It must consider the safety for each of the medicines in addition to their safety pattern related to the eventual switching procedure.

23 April 2025 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
BWBrian Li Han Wong
Brian Li Han Wong
GAGarry Aslanyan
Garry Aslanyan
WPWarisa Panichkriangkrai
Warisa Panichkriangkrai
RBRicardo Baptista-Leite
Ricardo Baptista-Leite
JMJemilah Mahmood
Jemilah Mahmood
ANAnders Nordström
Anders Nordström
Health diplomacy traditionally relies on consensus-building across nations, yet the accelerating integration of artificial intelligence (AI) into health systems poses new governance challenges. Rapidly changing geopolitical conditions—exemplified by shifts in U.S. global health funding and the expansion of AI beyond national boundaries—underscore the urgency of rethinking traditional approaches. This paper, based on insights from the Prince Mahidol Award Conference 2025 side meeting on “Navigating the Future: AI & Global Health Diplomacy,” examines how AI can reshape the practice of health diplomacy, both empowering and unsettling global health objectives. We first explore the promise of AI in enhancing disease surveillance, resource allocation, and progress toward universal health coverage. However, inadequate governance can exacerbate inequalities, particularly if AI remains in the hands of profit-focused enterprises or if digital divides persist. Health diplomacy, therefore, must expand its purview to include technical literacy, data ethics, and robust regulatory frameworks that safeguard equity and transparency in AI design and deployment. To illustrate these dynamics, we emphasise the interplay of social, political, commercial, and digital determinants of health, each feeding into AI-driven innovations. Strong diplomatic engagement is critical to ensuring that AI becomes a tool for mutual benefit rather than a catalyst for further fragmentation. Effective policies must integrate environmental sustainability considerations alongside cross-sector collaboration. We conclude that, although AI cannot replace the vital human element of negotiation and trust-building, it can substantially enhance global health outcomes when governed ethically and inclusively. The future of health diplomacy, shaped by AI, requires agile adaptation and unified strategies to preserve equity and planetary well-being.

25 September 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
RBRicardo Baptista-Leite
Ricardo Baptista-Leite
HLHenrique Lopes
Henrique Lopes
BVBjörn Vandewalle
Björn Vandewalle
JFJorge Félix
Jorge Félix
DFDiogo Franco
Diogo Franco
HBHelmut Brand
Helmut Brand
Background: Hepatitis C is a disease with a strong social component, as its main transmission route is via blood, making it associated with lifestyle. Therefore, it is suitable to be worked on from the perspective of public health policy, which still has a lot of room to explore and improve, contrary to diagnoses and treatments, which are already very refined and effective. Objective: An interactive gamified policy tool, designated as Let’s End HepC (LEHC), was created to understand the impact of policies related to hepatitis C on the disease’s epidemiology on a yearly basis until 2030. Methods: To this end, an innovative epidemiological model was developed, integrating Markov chains to model the natural history of the disease and adaptive conjoint analysis to reflect the degree of application of each of the 24 public health policies included in the model. This double imputation model makes it possible to assess a set of indicators such as liver transplant, incidence, and deaths year by year until 2030 in different risk groups. Populations at a higher risk were integrated into the model to understand the specific epidemiological dynamics within the total population of each country and within segments that comprise people who have received blood products, prisoners, people who inject drugs, people infected through vertical transmission, and the remaining population. Results: The model has already been applied to a group of countries, and studies in 5 of these countries have already been concluded, showing results very close to those obtained through other forms of evaluation. Conclusions: The LEHC model allows the simulation of different degrees of implementation of each policy and thus the verification of its epidemiological impact on each studied population. The gamification feature allows assessing the adequate fulfillment of the World Health Organization goals for the elimination of hepatitis C by 2030. LEHC supports health decision makers and people who practice patient advocacy in making decisions based on science, and because LEHC is democratically shared, it ends up contributing to the increase of citizenship in health. International Registered Report Identifier (IRRID): RR1-10.2196/38521

7 November 2024 in Primary Health Care Research & Development
Verified
Journal Article
Open access
PDF file
RBRicardo Baptista-Leite
Ricardo Baptista-Leite
HLHenrique Lopes
Henrique Lopes
DFDiogo Franco
Diogo Franco
TCTimo Clemens
Timo Clemens
HBHelmut Brand
Helmut Brand
Aim: This paper presents the development of the METRIC toolkit, aimed at enhancing primary healthcare interventions in the context of hepatitis C control, thus contributing to the World Health Organization’s global strategy to achieve the elimination of the disease by 2030. Background: At the global level, most people living with hepatitis C are unaware of their condition. As such, the eradication of hepatitis C necessitates comprehensive strategies within primary healthcare settings, as it provides an opportunity to reach the general population, facilitates the identification of potential patients who may be unfamiliar with hepatitis C, and guides them toward adequate care. Herein, we propose the METRIC toolkit as a means to optimize the efficiency and efficacy of healthcare services dedicated to hepatitis C control. Methods: The development of the METRIC toolkit was guided by a thorough review of pertinent literature, focusing on primary healthcare interventions in hepatitis C control. Key components were identified, encompassing systematic problem identification, solution formulation, outcome evaluation, and feedback integration. Findings: The METRIC toolkit represents a valuable resource for strengthening primary healthcare interventions in hepatitis C control. By fostering a culture of continuous improvement and data-driven decision-making, this framework holds promise in advancing the global agenda towards hepatitis C elimination. However, its successful application requires careful consideration of contextual factors and ongoing adaptation to local needs and circumstances.

16 May 2024 in Journal of Public Health
Verified
Journal Article
Open access
PDF file
RBRicardo Baptista-Leite
Ricardo Baptista-Leite
HLHenrique Lopes
Henrique Lopes
DFDiogo Franco
Diogo Franco
TCTimo Clemens
Timo Clemens
HBHelmut Brand
Helmut Brand
Aim: The “APPEAL” toolkit was developed to address the challenges in diagnosing people who inject drugs (PWID) with hepatitis C (HCV) and engaging them with healthcare systems. It introduces an ecosystemic approach based on health and well-being literacy across awareness, prevention and diagnosis dimensions of the hepatitis C’s care cascade (CC) for PWID. Subject and methods: The framework incorporated a scoping review and thematic analysis of 54 studies, alongside contributions from 57 hepatitis C key opinion leaders across seven countries. The toolkit is structured around five main axes: problems, solutions, outputs, outcomes and feedback process, employing a holistic perspective that considers economic, legal and social contexts. Eighteen policy prescriptions (PP) are proposed and supported by selective references to ensure relevance and applicability. Results: The APPEAL toolkit facilitates a strategic workflow for policymakers, health authorities and patient advocacy organizations, guiding them through action flowcharts to evaluate and enhance their interventions within the hepatitis C’s CC for PWID. Notably, its implementation demonstrated potential in identifying and attracting PWID to hepatitis C treatment pathways, contributing to increased diagnostics, education on risk behaviours and raising overall disease awareness. The toolkit’s intelligent cycle system supports accountability, enabling continuous data-driven improvement and innovation in addressing hepatitis C. Conclusion: The APPEAL toolkit was developed to attract PWID living with HCV to healthcare systems in a proactive manner. By managing information and fostering education on HCV, it aims to amplify awareness, prevention and diagnosis. The toolkit’s design and functionality underscore the importance of continuous quality improvement and the potential for its use in internal or external quality audits of healthcare services related to hepatitis C.

10 September 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
HLHenrique Lopes
Henrique Lopes
RBRicardo Baptista-Leite
Ricardo Baptista-Leite
CHCatarina Hermenegildo
Catarina Hermenegildo
RARifat Atun
Rifat Atun
Background: Influenza represents a critical public health challenge, disproportionately affecting at-risk populations, including older adults and those with chronic conditions, often compounded by socioeconomic factors. Innovative strategies, such as gamification, are essential for augmenting risk communication and community engagement efforts to address this threat. Objective: This study aims to introduce the “Let’s Control Flu” (LCF) tool, a gamified, interactive platform aimed at simulating the impact of various public health policies (PHPs) on influenza vaccination coverage rates and health outcomes. The tool aligns with the World Health Organization’s goal of achieving a 75% influenza vaccination rate by 2030, facilitating strategic decision-making to enhance vaccination uptake. Methods: The LCF tool integrates a selection of 13 PHPs from an initial set proposed in another study, targeting specific population groups to evaluate 7 key health outcomes. A prioritization mechanism accounts for societal resistance and the synergistic effects of PHPs, projecting the potential policy impacts from 2022 to 2031. This methodology enables users to assess how PHPs could influence public health strategies within distinct target groups. Results: The LCF project began in February 2021 and is scheduled to end in December 2024. The model creation phase and its application to the pilot country, Sweden, took place between May 2021 and May 2023, with subsequent application to other European countries. The pilot phase demonstrated the tool’s potential, indicating a promising increase in the national influenza vaccination coverage rate, with uniform improvements across all targeted demographic groups. These initial findings highlight the tool’s capacity to model the effects of PHPs on improving vaccination rates and mitigating the health impact of influenza. Conclusions: By incorporating gamification into the analysis of PHPs, the LCF tool offers an innovative and accessible approach to supporting health decision makers and patient advocacy groups. It enhances the comprehension of policy impacts, promoting more effective influenza prevention and control strategies. This paper underscores the critical need for adaptable and engaging tools in PHP planning and implementation. International Registered Report Identifier (IRRID): RR1-10.2196/55613